Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component parts into either the blood or urine, hence called non-secretory myeloma. Some non-secretory myeloma patients may produce the immunoglobulin proteins but they have defects in secretion. Due to lack of these protein biomarkers in blood and urine, it may be difficult to assess and treat the disease. Our myeloma panel is talking to Dr. Frits Van Rhee about latest developments and new options available in assessment and treatment of nonsecretory myeloma. Listen to podcast.
Dr. Frits van Rhee
Congratulations to the international expert, our own Dr. Frits van Rhee, on his newest publication, “A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease”.
Be sure to check it out!
Read here on Onctotarget
Full MCRI Show: Important Lessons Learned from the Measles Virus in Multiple Myeloma and the Next Step to Advance the Fascinating Viro Therapy with Dr. Frits van Rhee and Dr. Stephen Russell
The measles virus grabbed media attention with one patient’s amazing outcome. Dr. Russell and Dr. van Rhee hope to expand those results into more patients with lessons learned from the first clinical trials.
Be sure to listen to the show or read the transcript from the latest interview with the MyelomaCrowd funding initiative discussing the Measles Virus in Multiple Myeloma and Advancing Viro Therapy with our own Dr. Frits van Rhee and colleague Dr. Stephen Russell!